← Eichor
Study identifier: NCT05862337 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.

Condition: Hepatocellular Carcinoma  ·  Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

PhasePhase 3
Planned participants480
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

The primary objective of this study was to evaluate the efficacy of anlotinib hydrochloride capsules combined with penpulimab injection (test group) versus placebo (control group) for adjuvant therapy after radical surgery or ablation in HCC patients with high risk of recurrence by assessing recurrence-free survival (RFS).

This description comes directly from the study's public registry record.

Talk to the study team

Contact details are listed per location below or on the registry record.

Always discuss trial participation with your own doctor first.

Locations (67)

The First Affiliated Hospital of Bengbu Medical CollegeBengbu, Anhui, ChinaRecruiting
Anhui Provincial HospitalHefei, Anhui, ChinaRecruiting
The First Affiliated Hospital of Anhui Medical UniversityHefei, Anhui, ChinaNot Yet Recruiting
Peking Union Medical College HospitalBeijing, Beijing Municipality, ChinaRecruiting
Cancer Hospital Chinese Academy of Medical SciencesBeijing, Beijing Municipality, ChinaRecruiting
Peking University People's HospitalBeijing, Beijing Municipality, ChinaRecruiting
Beijing Friendship hospital of Capital Medical UniversityBeijing, Beijing Municipality, ChinaRecruiting
Beijing YouAn Hospital,Capital Medical UniversityBeijing, Beijing Municipality, ChinaRecruiting
Chongqing University Cancer HospitalChongqing, Chongqing Municipality, ChinaNot Yet Recruiting
Chongqing University Three Gorges HospitalChongqing, Chongqing Municipality, ChinaNot Yet Recruiting
Mengchao Hepatobiliary Hospital of Fujian MedicalFuzhou, Fujian, ChinaRecruiting
Fujian Cancer HospitalFuzhou, Fujian, ChinaRecruiting

+ 55 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05862337